Jazz Pharmaceuticals (JAZZ) Income towards Parent Company: 2009-2024
Historic Income towards Parent Company for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $561.8 million.
- Jazz Pharmaceuticals' Income towards Parent Company rose 16.77% to $251.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.9 million, marking a year-over-year increase of 21.63%. This contributed to the annual value of $561.8 million for FY2024, which is 34.45% up from last year.
- Latest data reveals that Jazz Pharmaceuticals reported Income towards Parent Company of $561.8 million as of FY2024, which was up 34.45% from $417.8 million recorded in FY2023.
- Over the past 5 years, Jazz Pharmaceuticals' Income towards Parent Company peaked at $561.8 million during FY2024, and registered a low of -$329.0 million during FY2021.
- Moreover, its 3-year median value for Income towards Parent Company was $417.8 million (2023), whereas its average is $255.2 million.
- In the last 5 years, Jazz Pharmaceuticals' Income towards Parent Company slumped by 236.17% in 2021 and then spiked by 295.13% in 2023.
- Yearly analysis of 5 years shows Jazz Pharmaceuticals' Income towards Parent Company stood at $241.6 million in 2020, then slumped by 236.17% to -$329.0 million in 2021, then soared by 34.90% to -$214.1 million in 2022, then soared by 295.13% to $417.8 million in 2023, then soared by 34.45% to $561.8 million in 2024.